Author

C. M. Coleman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Assay:imaging· 1 Assay:proteomics· 1

Frequent Co-Authors

A. G. Pockley· 1 shared A. Skinner· 1 shared E. Dubinina· 1 shared I. Daniels· 1 shared J. Delgado· 1 shared J. E. Dixon· 1 shared J. K. Ball· 1 shared J. Logue· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. G. Pockley

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologybioRxivPreprintJun 18, 2021

SARS-CoV-2 spike RBD and nucleocapsid encoding DNA vaccine elicits T cell and neutralising antibody responses that cross react with variants

V. A. Brentville, M. Vankemmelbeke, R. L. Methingham…·L. G. Durrant

This paper designs a DNA vaccine encoding SARS-CoV-2 spike RBD and nucleocapsid proteins, showing strong T cell responses and cross-reactive neutralizing antibodies against variants in mice.

DOI 10.1101/2021.06.18.448932

mouseproteomics

𝕏 PostBluesky

MicrobiologybioRxivPreprintMar 25, 2020

Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo

S. Weston, C. M. Coleman, R. Haupt…·M. Frieman

This study evaluates 20 FDA-approved drugs for antiviral activity against SARS-CoV-2 and SARS-CoV, finding 17 inhibit SARS-CoV-2 at non-cytotoxic concentrations and two protect mice from SARS-CoV disease.

DOI 10.1101/2020.03.25.008482

mouseexperimental assay

𝕏 PostBluesky